We are live on ! Find out more
FTH

Faeth Therapeutics
FTH

26 hedge funds and large institutions have $4.71M invested in Faeth Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more capital invested

Capital invested by funds: $3.92M → $4.71M (+$791K)

0.08% more ownership

Funds ownership: 0.43% → 0.51% (+0.08%)

0% more funds holding

Funds holding: 26 → 26 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

Holders
26
Holders Change
–
Holders Change %
0%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$571K
2
Morgan Stanley
Morgan Stanley
New York
+$190K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$130K
4
Bank of America
Bank of America
North Carolina
+$61.2K
5
Millennium Management
Millennium Management
New York
+$4.38K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$70.2K
2
WSL
Western Standard LLC
California
-$68.7K
3
VF
Virtu Financial
New York
-$39K
4
E
Ergoteles
New York
-$27.9K
5
Two Sigma Investments
Two Sigma Investments
New York
-$23.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
NM
1
Newtyn Management
New York
$2.31M +$571K +19,268 +33%
Vanguard Group
2
Vanguard Group
Pennsylvania
$860K – – –
Morgan Stanley
3
Morgan Stanley
New York
$193K +$190K +6,420 +53,500%
Renaissance Technologies
4
Renaissance Technologies
New York
$188K -$70.2K -2,368 -27%
BCM
5
Bridgeway Capital Management
Texas
$169K – – –
DFO
6
Duquesne Family Office
New York
$150K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$147K – – –
Bank of Montreal
8
Bank of Montreal
Ontario, Canada
$136K +$130K +4,395 New
Bank of America
9
Bank of America
North Carolina
$135K +$61.2K +2,065 +85%
Millennium Management
10
Millennium Management
New York
$105K +$4.38K +148 +4%
BlackRock
11
BlackRock
New York
$57.2K +$1.81K +61 +3%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$39.5K -$13.5K -455 -26%
Northern Trust
13
Northern Trust
Illinois
$39.1K – – –
State Street
14
State Street
Massachusetts
$38.7K – – –
E
15
Ergoteles
New York
$23.3K -$27.9K -941 -55%
Two Sigma Investments
16
Two Sigma Investments
New York
$22.9K -$23.4K -790 -51%
LB
17
Leo Brokerage
Texas
$22.3K +$22K +742 New
RJA
18
Raymond James & Associates
Florida
$21K -$7.41K -250 -26%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$17.4K – – –
DCM
20
Deuterium Capital Management
Florida
$16.5K -$1.33K -45 -8%
BCV
21
Banque Cantonale Vaudoise
Switzerland
$6K – – –
UBS Group
22
UBS Group
Switzerland
$5.16K +$3.47K +117 +213%
TRCT
23
Tower Research Capital (TRC)
New York
$3K -$237 -8 -8%
JP Morgan Chase
24
JP Morgan Chase
New York
$1K – – –
Wells Fargo
25
Wells Fargo
California
$188 – – –
1
2

FTH Hedge Fund Activity: Q1 2023 in Review

26 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2023, worth a combined $4.71M — up 20% from $3.92M a quarter earlier.

Fund positioning in FTH was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 7 trimmed.

The largest buyer was Newtyn Management, adding an estimated $571K. The largest seller was Renaissance Technologies, cutting an estimated $70.2K.

  • 26 institutional investors held Faeth Therapeutics (FTH) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $4.71M of Faeth Therapeutics stock for Q1 2023, up 20% quarter-over-quarter.
  • 3 funds opened new Faeth Therapeutics positions in Q1 2023 and 3 closed out, a net change of 0 holders.
  • The largest Faeth Therapeutics buyer in Q1 2023 was Newtyn Management, an estimated $571K added.
  • The largest Faeth Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $70.2K sold.

Based on aggregated 13F filings for Q1 2023.